Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease
References (26)
- et al.
Aetiology of Parkinson's disease
Lancet
(1983) The role of environmental toxins in the etiology of Parkinson's disease
Trends Neurosci.
(1989)- et al.
The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease
J. Neurol. Sci.
(1990) - et al.
MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isoenzyme (P450bufl, P450dbl)catalyzing debrisoquine4-hydroxylation
Biochem. Biophys. Res. Commun.
(1987) - et al.
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
Lancet
(1985) - et al.
Phenytoin 4-hydroxylation by rabbit liver P450IIC3 and identification of orthologs in human liver microsomes
Biochem. Biophys. Res. Commun.
(1990) - et al.
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450C29
Biochem. Biophys. Res. Commun.
(1991) - et al.
Cytochrome P450 and Parkinson's disease. Poor parahydroxylation of phenytoin
J. Neurol. Sci.
(1990) - et al.
Hepatic cytochrome P450 malfunction and Parkinson's disease
Lancet
(1986) - et al.
S-Methylation in motoneuron disease and Parkinson's disease
Lancet
(1989)
Mutant debrisoquine hydroxylation genes in Parkinson's disease
Lancet
(1992)
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
Lancet
(1992)
Chronic parkinsonism in humans due to a product of meperidineanalog synthesis
Science
(1983)
Cited by (6)
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: A self-perpetuating crosstalk?
2012, Biochimica et Biophysica Acta - Molecular Basis of DiseaseCitation Excerpt :Moreover, detoxification of medications and toxins is less efficient in PD patients compared to healthy individuals, thus possibly reflecting altered liver function [9]. Impaired capacity of hepatic P450 subsystems have been observed in late but not early onset PD patients [10,11] suggesting that hepatic alterations are not involved in the etiology of the disease but may emerge as a consequence of central neurodegenerative processes. Recent data indicate that brain dopaminergic systems represent an important center regulating hepatic cytochrome P450 activity [6,12,13].
Acetaldehyde and parkinsonism: Role of CYP450 2E1
2013, Frontiers in Behavioral NeuroscienceA review of xenobiotic metabolism enzymes in Parkinson's disease and motor neuron disease
2001, Drug Metabolism and Drug InteractionsPhenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
1999, Clinical Pharmacology and TherapeuticsP450 enzymes and Parkinson's disease: The story so far
1998, Movement Disorders
Copyright © 1994 Published by Elsevier B.V.